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Structured Abstract
Objectives – Craniosynostosis, the premature fusion of cranial bones,
has traditionally been described as a disease of increased bone minerali-
zation. However, multiple mouse models of craniosynostosis display cran-
iosynostosis simultaneously with diminished cranial bone volume and/or
density. We propose an alternative hypothesis that craniosynostosis
results from abnormal tissue mineralization through the downregulation of
tissue-non-specific alkaline phosphatase (TNAP) enzyme downstream of
activating mutations in FGFRs.
Material and Methods – Neonatal Crouzon (FGFRC342Y/+) and wild-type
(FGFR+/+) mice were injected with lentivirus to deliver a recombinant form
of TNAP. Mice were sacrificed at 4 weeks postnatal. Serum was collected
to test for alkaline phosphatase (AP), phosphorus, and calcium levels.
Craniofacial bone fusion and morphology were assessed by micro-com-
puted tomography.
Results – Injection with the TNAP lentivirus significantly increased serum
AP levels (increased serum AP levels are indicative of efficient transduc-
tion and production of the recombinant protein), but results were variable
and dependent upon viral lot and the litter of mice injected. Morphologi-
cal analysis revealed craniofacial form differences for inferior surface
(p = 0.023) and cranial height (p = 0.014) regions between TNAP lentivi-
rus-injected and vehicle-injected Crouzon mice. With each unit increase
in AP level, the odds of lambdoid suture fusion decreased by 84.2% and
these results came close to statistical significance (p = 0.068).
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Conclusion – These results suggest that TNAP deficiency may mediate
FGFR2-associated craniosynostosis. Future studies should incorporate
injection of recombinant TNAP protein, to avoid potential side effects and
variable efficacy of lentiviral gene delivery.
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Introduction
Craniosynostosis is a craniofacial anomaly char-
acterized by the premature fusion of cranial
bones. The only treatment for craniosynostosis
is surgery, which aimed to relieve elevated intra-
cranial pressure and normalize skull and facial
shapes (1–3). Specific genetic mutations occur in
association with craniosynostosis, including
mutations in the fibroblast growth factor recep-
tor (FGFR) gene family (4). However, the precise
molecular mechanism by which these mutations
cause craniosynostosis remains unknown.
Studies of mouse models of craniosynostosis
reveal the potential error in oversimplifying the
mechanism of craniosynostosis as being a dis-
order of excess cranial bone formation and/or
mineralization. That is, previous studies of
the FGFR2C342Y/+ mouse model of Crouzon
syndrome showed that these mice exhibit
craniosynostosis with decreased cranial bone
volume and density (5–7). Similarly, previous
investigations showed that the FGFR2S250W/+
mouse model of Apert syndrome exhibits cran-
iosynostosis with diminished cranial bone
thickness and formation (8), while the FGFR2
P253R/+ mouse model of Apert syndrome exhib-
its craniosynostosis with retarded endochondral
bone growth and ossification (9). In addition,
study of the FGFR3P244R/+ mouse model of Mu-
enke syndrome demonstrated that these
mice exhibit craniosynostosis with delayed
calvarial ossification and diminished bone den-
sity (10). Together, these results highlight the
possibility that the pathogenesis of craniosy-
nostosis may reflect an as-yet-unknown mech-
anism involving imbalanced bone and suture
mineralization.
Previous studies have shown that inorganic
phosphate (Pi) to pyrophosphate (PPi) concen-
tration ratios, as mediated by ectonucleotide py-
rophosphatase/phosphodiesterase 1 (Enpp1) and
tissue-non-specific alkaline phosphatase (TNAP),
control tissue mineralization (11). Enpp1 is the
primary enzymatic generator of PPi by bone-
forming cells (12). TNAP hydrolyzes PPi to Pi
and TNAP activity is essential for hydroxyapatite
crystal formation (13, 14). PPi not only inhibits
hydroxyapatite crystal deposition (15), but also
serves as an essential source of Pi to promote
mineralization after hydrolysis by TNAP (13, 14).
Additionally, while physiologic PPi levels inhibit
hydroxyapatite deposition, excess PPi can pro-
mote the pathologic deposition of non-apatitic
mineral crystals in soft tissues (16–18). PPi and
Pi can also influence tissue mineralization by
altering osteoblastic gene expression and behav-
ior (19–21). Notably, craniosynostosis occurs at a
high incidence in infants with hypophosphatasia
due to inactivating mutations in the gene for
TNAP (22, 23). These patients have severely defi-
cient bone mineralization (24, 25).
We propose that altered expression of enzymes
involved in PPi metabolism, downstream of FGF
signaling, could provide a molecular mechanism
for the aberrant mineralization phenotype of
FGFR-associated craniosynostosis. In support of
this hypothesis, we previously showed that FGF
signaling increases Enpp1 and inhibits TNAP
expression and activity in calvarial osteoblasts
(26, 27). Cells isolated from Crouzon
FGFR2C342Y/+ mice also exhibit diminished TNAP
mRNA and enzyme activity levels (7). These
data, combined with the clinical knowledge that
craniosynostosis occurs at high rates in patients
with deficient TNAP, support the idea that the
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pathogenesis of craniosynostosis involves dimin-
ished TNAP activity. To determine directly
whether diminished TNAP enzyme levels precip-
itate FGFR2-associated craniosynostosis, in this
study, we injected mice that carry the Crouzon
syndrome-associated FGFR2C342Y/+ mutation,
with lentivirus that allows for sustained expres-
sion of recombinant TNAP.
Materials and methods
FGFR2C342Y/+ mice
Animal procedures were performed according to
the University of Michigan’s Committee on Use
and Care of Animals. Mice carrying the Crouzon
syndrome FGFR2C342Y/+ mutation on the BALB/c
genetic background have a consistent craniofa-
cial phenotype involving craniofacial shape
changes and fusion of specific sutures (7). Geno-
typing of Crouzon (FGFR2C342Y/+) and wild-type
(FGFR2+/+) mice was performed as previously
described (5). Briefly, DNA from tail digests was
amplified by polymerase chain reaction using 50-
gagtaccatgctgactgcatgc-30 and 50-ggagaggcatctctg
tttcaagacc-30 primers. Genotypic ratios were as
predicted. Litter sizes ranged from 5 to 10 pups
per litter (avg = 7.5  3 pups per litter). Pups
were sacrificed at 4 weeks old for analysis. Blood
was collected by aortic puncture. Body weight
and length were measured.
Mineral-targeted TNAP lentivirus and injections
Mineral-targeted TNAP lentivirus was generously
provided by Dr. Jose Luis Millan (Sanford-Burn-
ham Medical Research Institute, La Jolla, CA).
This lentivirus expresses a fusion protein con-
taining TNAP enzyme fused at its C-terminal
end to a constant region of the human IgG1 Fc
domain and a deca-aspartate sequence (28). The
deca-aspartate sequence targets the enzyme to
hydroxyapatite (29).
In this study, five litters of mice (n = 32 pups:
eight wild-type male, eight wild-type female, six
Crouzon male and 10 Crouzon female) were
injected 3 days after birth with lentivirus
(1.0 9 107 transforming units per mouse) via the
jugular vein. Each litter was injected with a dif-
ferent viral lot/preparation. Four litters of mice
(n = 28 pups: seven wild-type male, seven wild-
type female, six Crouzon male and eight Crou-
zon female) were injected with an equivalent
volume of sterile phosphate-buffered saline
(vehicle).
Serum alkaline phosphatase activity, phosphate and
calcium analyses
Alkaline phosphatase (AP) activity serum levels
were quantified by spectrophotometry, using a
colorimetric reagent (SigmaFAST, Sigma-Aldrich
Co. LLC., St. Louis, MO). Alkaline phosphatase
activity units were calculated by comparison
with a standard curve. Serum AP levels are indic-
ative of efficient transduction and production of
the recombinant TNAP protein (28).
Inorganic phosphate and calcium quantifica-
tion was performed using commercially available
kits (Inorganic Phosphorus Reagent Set, Calcium
Reagent Set, Pointe Scientific, Inc., Canton, MI).
Inorganic phosphorus (mg/dl) and calcium (mg/
dl) levels were calculated by comparison with
standard curves.
Micro-computed tomography (micro-CT)
Whole skulls were dissected and fixed in ethanol.
Calvaria were embedded in 1% agarose and
scanned using a micro-CT system (lCT100
Scanco Medical, Bassersdorf, Switzerland) at 18-
lm voxel resolution. Scans were calibrated to
the manufacturer’s hydroxyapatite phantom.
Suture fusion assessment
Patency or fusion of craniofacial sutures was
established by serial viewing of individual slices
in the axial, sagittal, and coronal planes through-
out the entire length of the suture in question
using micro-CT scans (Microview version 2.1.2,
GE Healthcare PreClinical Imaging, London,
ON), as previously described (7). Fusion was ver-
ified by analysis of micro-CT scans by two inde-
pendent reviewers. Sutures analyzed included
the intersphenoidal suture (ISS), the spheno-
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occipital suture (SOS), the lambdoid suture, and
the sagittal suture. The coronal suture was not
analyzed due to difficulty of clear visualization
of this suture with the micro-CT equipment
and/or software used.
Three-dimensional craniofacial morphological analysis
Three-dimensional X, Y, and Z coordinate data
from 33 landmarks placed on micro-CT images
of mouse skulls were used to assess quantita-
tively craniofacial form in this study, as previ-
ously described (Fig. 1; 7, 30). Landmarks were
placed using orthodontic imaging software (Dol-
phin Imaging 11.0, Dolphin Imaging and Man-
agement Solutions, Chatsworth, CA). Reliability
of this method was previously reported (7).
Landmark coordinate data were imported into
analytic software (WinEDMA 1.0.1, Theodore
Cole, University of Missouri, Kansas City, MO).
This software uses three-dimensional coordinate
data to quantify and compare forms between
two sample populations by Euclidean distance
matrix analysis (EDMA), which allows for an
invariant statistical comparison of forms (31, 32).
In this study, we compared Crouzon mice
injected with the TNAP lentivirus (litters 1–4)
with Crouzon mice injected with vehicle (litters
6–9). Litter 5 was not used for analysis because
their serum alkaline phosphatase levels were
comparable to vehicle-injected mice, indicating
lack of efficacy of the virus in these mice. Land-
marks were grouped into regional subsets, due
to the high number of landmarks used.
Statistical analysis
Mice injected with the TNAP lentivirus displayed
varying levels of AP enzyme activity, indicating
variable efficacy of the virus. Therefore, logistic
regression was used to model the log odds
of the binary outcome of cranial suture or
Fig. 1. Three-dimensional cranio-
facial skeletal landmarks. Location
and description of thirty-three
craniofacial skeletal landmarks
placed on micro-CT scans of
mouse skulls are indicated.
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synchondrosis fusion. This statistical model
allowed us to draw conclusions about the rela-
tionship between the level of AP enzyme activity
and our ability to influence suture fusion,
despite the variability in AP enzyme activity lev-
els between mice. Linear regression was used to
analyze the effect of the AP level, genotype, and
gender on continuous outcomes including body
weight, body length, serum inorganic phospho-
rus, and serum calcium levels.
Results
Serum alkaline phosphatase activity
Injection with the lentivirus significantly
increased serum alkaline phosphatase (AP) activ-
ity levels, when compared to vehicle-injected
mice (Fig. 2A). Vehicle-injected wild-type mice
had a mean AP level of 0.05  0.02 units; vehi-
cle-injected Crouzon mice had a mean level of
0.05  0.01 units; TNAP lentivirus-injected wild-
type mice had a mean AP level of 0.63  0.49
units and TNAP lentivirus-injected Crouzon
mice had a mean AP level of 0.60  0.46 units.
Despite injecting similar titers of virus, AP levels
were variable and dependent upon the lot of
virus/litter injected (Fig. 2B). Litter 1 had the
highest AP activity, with an average level of
1.2  0.27 units. Litter 2 had an average AP level
of 0.79  0.15 units, while litters 3 and 4 had even
lower levels. Litter 3 had an average AP level of
0.27  0.09 units, and litter 4 had an average AP
level of 0.30  0.10 units. Litter 5 was injected
with the lentivirus but showed AP activity similar
to that seen in control mice (mean AP level was
0.07  0.05 units). No differences between geno-
types and genders were found.
Body weight and body length measurements
With every unit increase in AP activity, there was
a decrease in body weight by 1.4 g for both
Crouzon (FGFR2C342Y/+) and wild-type (FGFR2+/+)
mice (p = 0.004) (Table 1). Crouzon mice
weighed on average 2.9 g less than wild-type
mice, regardless of AP level (p < 0.0001). The
influence of AP level on body weight was
the same for both wild-type and Crouzon mice.
The overall R2 value was 0.519 (overall
p < 0.0001) which means that the regression
A
B
Fig. 2. Serum alkaline phospha-
tase enzyme activity levels by
genotype, treatment group, and
litter of mice. (A) Serum alkaline
phosphatase enzyme activity lev-
els of TNAP lentivirus-injected vs.
vehicle-injected mice. *p < 0.05
vs. vehicle-injected mice. WT =
wild-type mice, CZ = Crouzon
mice, virus = TNAP lentivirus
injected, vehicle = vehicle injected.
(B) Serum alkaline phosphatase
enzyme activity levels by litter of
mice. Litters 1–5 were injected
with the TNAP lentivirus. Litters
6–9 were injected with vehicle.
*Indicates significant difference
between TNAP lentivirus-injected
values of each litter, compared to
all vehicle-injected mice, where
p < 0.05.
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model (including AP level, genotype, and gender
as variables) accounted for 51.9% of the variabil-
ity in weight.
With every unit increase in AP level, there was
a decrease in body length by 4.5 mm for both
Crouzon and wild-type mice (p < 0.003)
(Table 1). Crouzon mice on average measure
6.5 mm less than wild-type mice, regardless of
AP level (p < 0.0001), and there is no statistically
significant interaction between AP level and
genotype. The overall R2 value was 0.395 (overall
p < 0.0001) which means that the regression
model (including AP level, genotype, and gender
as variables) accounted for 39.5% of the variabil-
ity in body length.
Serum inorganic phosphorus and calcium assays
Neither injection with the TNAP lentivirus, gen-
der, nor genotype had a significant effect on
serum phosphorus levels. Vehicle-injected wild-
type mice had a mean serum inorganic phos-
phorous level of 10.2  1.3 mg/dl; vehicle-
injected Crouzon mice had a mean serum inor-
ganic phosphorous level of 10.3  2.8 mg/dl;
TNAP lentivirus-injected wild-type mice had a
mean serum inorganic phosphorous level of
9.5  1.2 mg/dl; and TNAP lentivirus-injected
Crouzon mice had a mean serum inorganic
phosphorous level of 9.3  1.3 mg/dl. With
every unit increase in AP level, there was an
increase in serum inorganic phosphorous by
1.0 mg/dl for Crouzon and by 0.6 mg/dl for
wild-type mice, but these differences were not
statistically significant (p = 0.10 for Crouzon,
p = 0.24 for wild type). The corresponding R2
values for Crouzon and wild-type mice were
0.094 and 0.050, respectively, which means that
the regression model (including AP level, geno-
type, and gender as variables) accounted for
only 9.4% and 5.0% of the variability in serum
inorganic phosphate in Crouzon and wild-type
mice, respectively.
Injection with the TNAP lentivirus, gender, and
genotype also did not significantly influence
serum calcium levels. Vehicle-injected wild-type
mice had a mean serum calcium level of
9.1  0.4 mg/dl; vehicle-injected Crouzon mice
had a mean serum calcium level of
8.9  0.5 mg/dl; TNAP lentivirus-injected wild-
Table 1. Body Weight and Length as Inﬂuenced by AP level, genotype, and gender




Lower bound Upper bound
Body Weight (g) R2 = 0.519
p < 0.0001
Intercept 14.04











Body Length (mm) R2 = 0.395
p < 0.0001
Intercept 78.38
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type mice had a mean serum calcium level of
8.6  0.3 mg/dl; and TNAP lentivirus-injected
Crouzon mice had a mean serum calcium level
of 8.5  0.4 mg/dl. With every unit increase in
AP level, there was an increase in serum calcium
by 0.4 mg/dl for Crouzon and by 0.1 mg/dl for
wild-type mice. While this increase was signifi-
cant for Crouzon mice (p < 0.05 for Crouzon,
p = 0.72 for wild type), regression analysis incor-
porating all three variables (AP level, gender,
and genotype) revealed a lack of significance
(p = 0.228), demonstrating that AP level did not
have a significantly effect on serum calcium. The
corresponding R2 values for Crouzon and wild-
type mice were 0.135 and 0.005, respectively,
which means that the regression model (includ-
ing AP level, genotype, and gender as variables)
accounted for only 13.5% and 0.5% of the vari-
ability in serum inorganic phosphate in Crouzon
and wild-type mice, respectively.
Suture fusion
All Crouzon mice, regardless of treatment, exhib-
ited fusion of the intersphenoidal synchondrosis
(ISS). No wild-type mice, regardless of treat-
ment, exhibited fusion of the sagittal suture. The
spheno-occipital synchondrosis (SOS) was fused
in 28.6% of vehicle-injected Crouzon mice and
in 25.0% of TNAP lentivirus-injected Crouzon
mice. The lambdoid suture was fused in 61.9%
of vehicle-injected Crouzon mice and in 56.3%
of TNAP lentivirus-injected Crouzon mice
(Fig. 3A).
Injection with the TNAP lentivirus resulted in
higher expression levels in mouse litter 1 and lit-
ter 2, than in subsequent litters. When compar-
ing these two litters of TNAP lentivirus-injected
mice with all vehicle-injected mouse litters, the
SOS was fused into 28.6% of vehicle-injected
Crouzon mice and into 14.3% of TNAP lentivi-
rus-injected Crouzon mice. The lambdoid suture
was fused into 61.9% of vehicle-injected Crouzon
mice and into 28.6% of TNAP lentivirus-injected
Crouzon mice (Fig. 3B).
To account for the variable efficacy of injected
virus, we next performed logistic regression
analysis to assess the effect of AP level on suture
fusion in Crouzon mice. For every unit increase
in AP level, the odds of fusion of the SOS
decreased by 41.7% (Table 2). However, the p
value did not reach significance (p = 0.602). For
every unit increase in AP level, the odds of
fusion of the lambdoid suture decreased by
84.2%. This result falls just short of significance
(p = 0.068) (Table 2).
Morphological analysis
The craniofacial subset comparisons that were
significantly different between TNAP lentivirus-
injected and vehicle-injected Crouzon mice were
for the inferior surface (p = 0.02) and cranial
vault vertical (p = 0.01) regions (Table 3). Skull
vertical height dimensions were diminished in
TNAP lentivirus-injected Crouzon mice, when
compared to vehicle-injected Crouzon mice (sig-
A
B
Fig. 3. Percentage of TNAP lentivirus-injected vs. vehicle-
injected Crouzon mice with cranial suture and synchondrosis
fusion. (A) Fusion percentages of vehicle-injected and TNAP
lentivirus-injected Crouzon mice, combining all litters of
mice (litters 1–5 for TNAP lentivirus injected, litters 6–9 for
vehicle injected). (B) Fusion percentages of vehicle injected
and only litter 1 and litter 2 of TNAP lentivirus-injected
Crouzon mice. CZ = Crouzon vehicle injected, CZ-tx = Crou-
zon TNAP lentivirus injected, ISS = intersphenoidal sync-
hondrosis, SOS = sphenoccipital synchondrosis, control =
vehicle injected.
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nificant form estimate confidence intervals for
landmarks 5–30, 5–28, 5–29, 4–28, 4–29). Skull
transverse dimensions were also diminished in
TNAP lentivirus-injected Crouzon mice, when
compared to vehicle-injected Crouzon mice (sig-
nificant form estimate confidence intervals for
landmarks 24–25, 12–13).
Discussion
This study describes effects of a TNAP lentivirus
on Crouzon (FGFR2C342Y/+) mice to assess its
potential as a therapeutic drug for craniosynos-
tosis. Ideally, such a drug would decrease the
degree of suture fusion so as to minimize the
craniofacial dysmorphology and intracranial
pressure that can be caused by craniosynostosis.
Overexpression of TNAP also tests our hypothe-
sis that FGFR2 gain-of-function mutations sup-
press TNAP expression thereby causing
abnormalities in craniofacial bone and suture
mineralization. Previous studies have systemi-
cally overexpressed TNAP in mice and humans
for the treatment of the skeletal hypomineraliza-
tion seen in hypophosphatasia (28, 32–34). This
is the first study to specifically analyze the cra-
niofacial effects of TNAP.
Lentivirus is a useful form of drug provision
because it requires only a single injection for
sustained delivery, as the viral genome integrates
into the host cell genome for stable expression
of the encoded protein. Previous studies using
this recombinant TNAP lentivirus achieved
increased serum AP levels and significant reduc-
tions in long bone hypomineralization in the
TNAP null mouse model of infantile hypophos-
phatasia, indicating that the virus is efficacious
(28). In this study, TNAP lentivirus produced a
significant increase in serum alkaline phospha-
tase levels compared to those of vehicle-injected
mice, but the efficacy of the injection was vari-
able, dependent upon the litter injected. This
variability in AP level may be due to many fac-
tors including inaccurate titer of virus (each lit-
ter was injected with a different lot of virus), and
variations in viral integration and replication
within the host. The variation in AP level seren-
dipitously allowed us to test a dose–response
relationship between AP level and body weight,
body size, craniosynostosis, and craniofacial
morphology using linear and logistic regression
analyses. A limitation of the regression analyses
performed in this study is the small number of
mice with high serum AP levels in lentivirus-
injected mice. Future studies should include
injection of additional mice with virus to attain
more mice with higher serum AP levels.
In this study, serum AP level had a diminish-
ing effect on body weight and length regardless
of gender or genotype, suggesting that the TNAP
Table 2. Cranial suture and synchondrosis fusion as Inﬂuenced by Alkaline Phosphatase (AP) level
Suture or Synchondrosis Parameter Coefficient (b) with p value
95% Confidence intervals
Odds ratio for fusionLower bound Upper bound
Lambdoid AP level 1.85
p < 0.068
0.02 1.14 84.2%
Spheno-occipital Synchondrosis AP level 0.54
p < 0.602
0.08 4.4 41.7%







Superior surface 9 0.080
Inferior surface 9 0.023*
Lateral surface 9 0.657
Cranial vault vertical 7 0.014*
Cranial vault transverse 7 0.496
*Indicates statistical signiﬁcance between treatment groups.
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lentivirus had a negative effect on overall
growth. Similar reductions in growth as reflected
by body weight were reported upon injection of
TNAP null mice with the TNAP lentivirus (28).
Because injection with the same TNAP protein
that is encoded in this lentivirus previously led
to increased weight gain in injected mice (33),
we suspect that the lentivirus itself in some
manner inhibits body growth and weight gain.
Future studies should incorporate injection of
the recombinant TNAP protein, to avoid both
potential side effects and the variable efficacy of
lentiviral delivery.
Suture fusion analysis was difficult, due to the
small number of mice with high serum AP activ-
ity. When all lentivirus-treated mice were
grouped together, minimal differences in fusion
of cranial sutures or cranial base synchondroses
were seen. When TNAP lentivirus-injected mice
only with higher serum AP levels are compared
with vehicle-injected mice, the incidence of
lambdoid suture fusion decreased from 61.9% to
28.6% and the incidence of SOS fusion decreased
from 28.6% to 14.3%. Logistic regression showed
that the odds of lambdoid suture fusion
decreased by 84.2%. However, these results were
not statistically significant (p = 0.068). Clearly,
more mice injected with TNAP lentivirus and
exhibiting high levels of AP activity are required
to definitively show an effect of TNAP on crani-
osynostosis.
Crouzon mice on the BALB/c genetic strain
are significantly different in craniofacial mor-
phology than wild-type mice (7). In this study,
EDMA analysis was used to determine whether
the TNAP lentivirus altered the craniofacial form
of injected Crouzon mice. Due to the large num-
ber of landmarks utilized, the craniofacial skele-
ton was divided into spacial regions. The inferior
craniofacial surface and the cranial vault vertical
regions were significantly different between
TNAP lentivirus-injected and vehicle-injected
mice. These results suggest that TNAP lentivirus
treatment may rescue the craniofacial form of
Crouzon mice. More specifically, it has been
shown that skull width and height of Crouzon
mice are increased when compared to that of
wild-type mice (6). EDMA results of this study
revealed that vertical and transverse dimensions
were diminished in TNAP lentivirus-injected
Crouzon mice when compared to vehicle-
injected Crouzon mice, suggesting the possibility
that delivery of the recombinant TNAP enzyme
rescues these abnormalities in shape. It is
important to remember that this analysis was
based upon mice grouped by treatment, and as
previously stated, AP level varied to such an
extent in treated mice that this grouping may
not be able to detect fully the effects of the
treatment on craniofacial form.
Conclusions
Lentiviral delivery of recombinant TNAP caused
a decrease in overall growth of the mice com-
pared to vehicle-injected mice. EDMA analysis
revealed that there were regional craniofacial
form effects of the TNAP lentivirus injection
compared to vehicle injection treatments. The
virus injection treatment also appeared to
diminish fusion of the lambdoid suture,
although studies incorporating a greater number
of mice with higher serum AP levels are required
to establish significance. If TNAP has a signifi-
cant role in the etiology of craniosynostosis,
TNAP enzyme replacement therapies currently
used to treat mineralization defects in hypo-
phosphatasia patients (25) could be used to pre-
vent and/or treat craniosynostosis.
Clinical relevance
Craniosynostosis occurs in association with acti-
vating mutations in fibroblast growth factor
receptors and inactivating mutations in TNAP
(tissue-non-specific alkaline phosphatase).
Because FGF signaling regulates TNAP expres-
sion and because TNAP is an established media-
tor of tissue mineralization, we hypothesize that
dysregulation of TNAP downstream of mutant
FGF receptors leads to craniosynostosis and
associated abnormalities. To test this hypothesis,
here we injected Crouzon mice with lentivirus
expressing TNAP. While variable, our results sug-
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gest that delivery of TNAP may diminish the
degree of craniofacial skeletal malformation seen
in the FGFR2C342Y/+ mouse model of Crouzon
craniosynostosis.
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